Cyproheptadine Hydrochloride is a human prescription drug labeled by 'Proficient Rx Lp'. National Drug Code (NDC) number for Cyproheptadine Hydrochloride is 71205-989. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Cyproheptadine Hydrochloride drug includes Cyproheptadine Hydrochloride - 4 mg/1 . The currest status of Cyproheptadine Hydrochloride drug is Active.

Cyproheptadine hydrochloride cyproheptadine hydrochloride cyproheptadine hydrochloride cyproheptadine lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate type a potato it;68

Drug interactions mao inhibitors prolong and intensify the anticholinergic effects of antihistamines. antihistamines may have additive effects with alcohol and other cns depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

Indications and usage perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild, uncomplicated allergic skin manifestations of urticaria and angioedema. amelioration of allergic reactions to blood or plasma cold urticaria dermatographism as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Warnings pediatric patients overdosage of antihistamines, particularly in infants and young children, may produce hallucinations, central nervous system depression, convulsions, respiratory and cardiac arrest, and death. antihistamines may diminish mental alertness; conversely, particularly, in the young child, they may occasionally produce excitation. cns depressants antihistamines may have additive effects with alcohol and other cns depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. activities requiring mental alertness patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery. antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients (see precautions, geriatric use ).

General cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with: history of bronchial asthma increased intraocular pressure hyperthyroidism cardiovascular disease hypertension

Dosage and administration dosage should be individualized according to the needs and the response of the patient. each tablet contains 4 mg of cyproheptadine hydrochloride. pediatric patients age 2 to 6 years the total daily dosage for pediatric patients may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day or 8 mg per square meter of body surface (8 mg/m 2 ). the usual dose is 2 mg (½ tablet) two or three times a day, adjusted as necessary to the size and response of the patient. the dose is not to exceed 12 mg a day. age 7 to 14 years the usual dose is 4 mg (1 tablet) two or three times a day adjusted as necessary to the size and response of the patient. the dose is not to exceed 16 mg a day. adults the total daily dose for adults should not exceed 0.5 mg/kg/day. the therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg a day. an occasional patient may require as much as 32 mg a day for adequate relief. i Read more...

Contraindications newborn or premature infants this drug should not be used in newborn or premature infants. nursing mothers because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. other conditions hypersensitivity to cyproheptadine and other drugs of similar chemical structure. monoamine oxidase inhibitor therapy (see drug interactions .) angle-closure glaucoma stenosing peptic ulcer symptomatic prostatic hypertrophy bladder neck obstruction pyloroduodenal obstruction elderly, debilitated patients

Adverse reactions adverse reactions which have been reported with the use of antihistamines are as follows: central nervous system sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness. integumentary allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity. special senses acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus. cardiovascular hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock. hematologic hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia. digestive system cholestasis, hepatic failure, hepatitis, hepatic function abnormality, dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation, jaundice. genitourinary urinary frequency, difficult urination, urinary retention, early m Read more...

Drug interactions mao inhibitors prolong and intensify the anticholinergic effects of antihistamines. antihistamines may have additive effects with alcohol and other cns depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

Pregnancy pregnancy category b reproduction studies have been performed in rabbits, mice, and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. no teratogenic effects were observed in any of the newborns. nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed.

Pediatric use safety and effectiveness in pediatric patients below the age of two have not been established (see contraindications, newborn or premature infants , and warnings, pediatric patients ).

Geriatric use clinical studies of cyproheptadine hcl tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see warnings, activities requiring mental alertness ).

Overdosage antihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in pediatric patients. also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur. if vomiting has not occurred spontaneously , the patient should be induced to vomit with syrup of ipecac. if patient is unable to vomit , perform gastric lavage followed by activated charcoal. isotonic or ½ isotonic saline is the lavage of choice. precautions against aspiration must be taken especially in infants and children. when life threatening cns signs and symptoms are present, intravenous physostigmine salicylate may be considered. dosage and frequency of administration are dependent on age, clinical response, and recurrence after response. (see package circulars for physostigmine products.) saline cathartics , as milk of magnesia , by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content. stimulants should not be used. vasopressors may be used to treat hypotension. the oral ld 50 of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.

Description cyproheptadine hcl usp is an antihistaminic and antiserotonergic agent. cyproheptadine hydrochloride usp is a white to slightly yellowish crystalline solid, with a molecular weight of 350.89, which is soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform, and practically insoluble in ether. it is the sesquihydrate of 4-(5 h -dibenzo [a,d] cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. the molecular formula of the anhydrous salt is c 21 h 21 n∙hcl and the structural formula of the anhydrous salt is: c 21 h 21 n∙hcl m.w. 350.89 cyproheptadine hydrochloride usp is available for oral administration in 4 mg tablets. inactive ingredients include: lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. chemical structure

Clinical pharmacology cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites. pharmacokinetics and metabolism after a single 4 mg oral dose of 14 c-labelled cyproheptadine hcl in normal subjects, given as tablets, 2 to 20% of the radioactivity was excreted in the stools. only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. at least 40% of the administered radioactivity was excreted in the urine. no detectable amounts of unchanged drug were present in the urine of patients on chronic 12 to 20 mg daily doses. the principle metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. elimination is diminished in renal insufficiency.

Pharmacokinetics and metabolism after a single 4 mg oral dose of 14 c-labelled cyproheptadine hcl in normal subjects, given as tablets, 2 to 20% of the radioactivity was excreted in the stools. only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. at least 40% of the administered radioactivity was excreted in the urine. no detectable amounts of unchanged drug were present in the urine of patients on chronic 12 to 20 mg daily doses. the principle metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. elimination is diminished in renal insufficiency.

Carcinogenesis, mutagenesis, impairment of fertility long-term carcinogenic studies have not been done with cyproheptadine. cyproheptadine had no effect on fertility in a two-litter study in rats or a two generation study in mice at about 10 times the human dose. cyproheptadine did not produce chromosome damage in human lymphocytes or fibroblasts invitro ; high doses (10-4m) were cytotoxic. cyproheptadine did not have any mutagenic effect in the ames microbial mutagen test; concentrations of above 500 mcg/plate inhibited bacterial growth.

How supplied cyproheptadine hydrochloride tablets usp, 4 mg are available as white to off-white round convex tablets, engraved it above bisect and 68 below bisect on one side with other side is plain, containing 4 mg of cyproheptadine hcl packaged in bottles of 30 (ndc 71205-989-30), 60 (ndc 71205-989-60), 90 (ndc 71205-989-90), 100 (ndc 71205-989-00), 120 (ndc 71205-989-72), 180 (ndc 71205-989-78), 240 (ndc 71205-989-64), 270 (ndc 71205-989-67), 360 (ndc 71205-989-76) and 1000 (ndc 71205-989-11) tablets. pharmacist: dispense in a well-closed container as defined in the usp, with a child-resistant closure (as required). store at 20°c to 25°c (68°f to 77°f) [see usp controlled room temperature].

Information for patients antihistamines may diminish mental alertness; conversely, particularly, in the young child, they may occasionally produce excitation. patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

Principal display panel - 4 mg tablet bottle label ndc 71205-989-00 rx only cyproheptadine hydrochloride tablets, usp 4 mg 100 tablets 71205-989-30